Other Product Sample Clauses
The "Other Product" clause defines how products or services not explicitly listed in the main agreement are treated. Typically, this clause clarifies whether additional products offered by the supplier are included under the same terms or require separate negotiation. For example, if a vendor introduces a new software module after the contract is signed, this clause determines if it is automatically covered or excluded. Its core function is to prevent ambiguity regarding the inclusion of future or ancillary products, ensuring both parties understand the scope of the agreement and reducing the risk of disputes over unlisted items.
Other Product. Acceptance of Product that is not First Order Product shall occur as follows:
Other Product. (a) [ * ].
(b) [ * ].
Other Product. Other Product Commercial Milestone Event [*] Commercial Milestone Payment
Other Product. “Other Product” shall mean any and all finished drug product formulations containing (i) any Product Candidate which is directed to any target other than HBV and selected by Purchaser pursuant to Section 1.3(a)(ii), or (ii) any derivative or variant or other modification of the foregoing.
Other Product. The term “Other Product” shall mean any Licensed Product for use in the Field which is not an Antibody Product or a Vaccine Product.
Other Product. The term “Other Product” shall mean any product that is not itself a Licensed Product but that:
Other Product. During the Term, Licensee shall have a right of first negotiation on a product-by-product basis with respect to television exhibition rights controlled by HED for any new television product produced, co-produced or acquired by HED which does not fall under this agreement (i.e., specials, documentaries, etc.). The parties agree to negotiate in good faith with respect to any such product for a period of 45 days. HED will negotiate exclusively with Licensee during such period. If HED and Licensee fail to reach an agreement within such 45-day period, HED will not thereafter offer the product to a third party on terms more favorable than those offered to HED by Licensee.
Other Product. Licensee shall have a right of first negotiation with respect to acquiring for broadcast on the Service any television product which is not covered by this Agreement for which HEDC, Hallmark Entertainment, Inc. or any subsidiary of Hallmark Entertainment, Inc. controls the rights in the Territory during the Term, whether produced prior to or after the date of this Agreement, subject to those existing output distribution arrangements identified on Schedule "C" attached hereto.
Other Product. 14.1 In the event that during the term of this Agreement (i) Aventis (or one of its Affiliates) signs a definitive agreement with a third party by which Aventis (or one of its Affiliates) would acquire, directly or indirectly, Control (as such term is defined below) of such third party, or by which a third party would acquire, directly or indirectly, Control of Aventis (or one of its Affiliates), and (ii) the third party (or one of its Affiliates) is the owner of or is holding license rights to patents relating to another GLP-1 receptor agonist (for the purpose of this Article 14 referred to as “Other Product”), and (iii) such Other Product, at the moment of acquiring Control, is in clinical development, is approved or is commercialized in either [***], then Aventis shall notify Zealand thereof in writing within one hundred and twenty (120) days (the “Aventis Notice”). This period, however, is reduced to sixty (60) days in the event that the Other Product is one of the primary assets of such third party. In the Aventis Notice Aventis shall confirm that it intends to divest or cease the development or the commercialization of the Other Product. If Aventis does not so notify Zealand in writing within such one hundred and twenty (120) days, or if applicable sixty (60) days, then Aventis shall be deemed to be in material breach of this Agreement. However, if Aventis has notified Zealand in writing within such one hundred and twenty (120) days, or if applicable sixty (60) days, and as long as Aventis is dedicating [***] efforts to develop and commercialize the Compound or Product and is working as expeditiously as reasonably possible towards divesting (including licensing-out) the Other Product or towards ceasing the development or the commercialization thereof, Aventis shall not be deemed to be in material breach of this Agreement. Without limiting the generality of the foregoing, Aventis shall in any event complete the divesting or cease the development or the commercialization of the Other Product, as the case may be, within twelve (12) months from Zealand’s receipt of the Aventis Notice. For the purpose of this Article 14, the term “Control” shall mean the ownership of fifty (50) percent or more of the voting stock or similar interest.
Other Product. 14.1 In the event that during the term of this Agreement (i) Aventis (or one of its Affiliates) signs a definitive agreement with a third party by which Aventis (or one of its Affiliates) would acquire, directly or indirectly, Control (as such term is defined below) of such third party, or by which a third party would acquire, directly or indirectly, Control of Aventis (or one of its Affiliates), and (ii) the third party (or one of its Affiliates) is the owner of or is holding license rights to patents relating to another GLP-1 receptor agonist (for the purpose of this Article 14 referred to as “Other Product”), and (iii) such Other Product, at the moment of acquiring Control, is in clinical development, is approved or is commercialized in either [***], then Aventis shall notify Zealand thereof in writing within one hundred and twenty (120) days (the “Aventis Notice”). This period, however, is reduced to sixty (60) days in the event that the Other Product is one of the primary assets of such third party. In the Aventis Notice Aventis shall confirm that it intends to divest or cease the development or the commercialization of the Other Product. If Aventis does not so notify Zealand in writing within such one hundred and twenty (120) days, or [***] Certain information in this document has been omitted and submitted separately to the Securities and Exchange Commission. Confidential treatment has been requested separately with respect to the omitted portions.